Preclinical Assessment of Young Blood Plasma for Alzheimer Disease

Jinte Middeldorp, Benoit Lehallier, Saul A Villeda, Suzanne S M Miedema, Emily Evans, Eva Czirr, Hui Zhang, Jian Luo, Trisha Stan, Kira I Mosher, Eliezer Masliah, Tony Wyss-Coray

Research output: Contribution to JournalArticleAcademicpeer-review


Importance: Alzheimer disease (AD) pathology starts long before clinical symptoms manifest, and there is no therapy to treat, delay, or prevent the disease. A shared blood circulation between 2 mice (aka parabiosis) or repeated injections of young blood plasma (plasma from 2- to 3-month-old mice) into old mice has revealed benefits of young plasma on synaptic function and behavior. However, to our knowledge, the potential benefit of young blood has not been tested in preclinical models of neurodegeneration or AD.

Objectives: To determine whether young blood plasma ameliorates pathology and cognition in a mouse model for AD and could be a possible future treatment for the disease.

Design, Setting, and Participants: In this preclinical study, mice that harbor a human mutant APP gene, which causes familial AD, were aged to develop AD-like disease including accumulation of amyloid plaques, loss of synaptic and neuronal proteins, and behavioral deficits. The initial parabiosis studies were done in 2010, and the final studies were conducted in 2014. Alzheimer disease model mice were then treated either by surgically connecting them with a young healthy mouse, thus providing a shared blood circulation through parabiosis, or through repeated injections of plasma from young mice.

Main Outcomes and Measures: Neuropathological parameters and changes in hippocampal gene expression in response to the treatment were assessed. In addition, cognition was tested in AD model mice intravenously injected with young blood plasma.

Results: Aged mutant amyloid precursor protein mice with established disease showed a near complete restoration in levels of synaptic and neuronal proteins after exposure to young blood in parabiosis (synaptophysin P = .02; calbindin P = .02) or following intravenous plasma administration (synaptophysin P < .001; calbindin P = .14). Amyloid plaques were not affected, but the beneficial effects in neurons in the hippocampus were accompanied by a reversal of abnormal extracellular receptor kinase signaling (P = .05), a kinase implicated in AD. Moreover, young plasma administration was associated with improved working memory (P = .01) and associative memory (P = .02) in amyloid precursor protein mice.

Conclusions and Relevance: Factors in young blood have the potential to ameliorate disease in a model of AD.

Original languageEnglish
Pages (from-to)1325-1333
Number of pages9
JournalJAMA Neurology
Issue number11
Publication statusPublished - 1 Nov 2016


  • Ageing
  • Alzheimer Disease
  • APP mouse model
  • Parabiosis
  • Young blood
  • Hippocampal synaptic plasticity
  • Amyloid-beta plaques
  • Cognition
  • working memory
  • associative learning


Dive into the research topics of 'Preclinical Assessment of Young Blood Plasma for Alzheimer Disease'. Together they form a unique fingerprint.

Cite this